FDA won petition to have ruling reconsidered

Share this article:
The FDA has won a petition to have the US Court of Appeals for the District of Columbia reconsider a ruling that mentally competent terminally ill patients should have access to post-Phase I investigational drugs if there are no government-approved alternatives.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions